Gracell presents clinical data from FasTCAR-T GC012F

Gracell Biotechnologies “presented updated results from the clinical investigator-initiated trial of GC012F for treatment of newly diagnosed multiple myeloma as an oral presentation at the 65th American Society of Hematology Annual Meeting & Exposition taking place in San Diego, California and online. GC012F demonstrated a 100% overall response rate and 95% MRD- sCR rate among 22 transplant-eligible, high-risk NDMM patients as of the data cutoff date of October 1, 2023. The data included longer-term follow-up from the initial 16 patients, for whom earlier results were presented at the 2022 American Society for Hematology Annual Meeting, plus six additional patients that were enrolled and treated later. The data also showed that GC012F was well-tolerated with no new safety signals observed in this frontline application of CAR-T therapy.”